{"id":904341,"date":"2025-11-03T11:32:26","date_gmt":"2025-11-03T16:32:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/"},"modified":"2025-11-03T11:32:26","modified_gmt":"2025-11-03T16:32:26","slug":"galecto-to-highlight-gb3226-program-at-ash-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/","title":{"rendered":"Galecto to Highlight GB3226 Program at ASH 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML)<\/p>\n<p><\/em>\n        <\/li>\n<\/ul>\n<p>BOSTON, Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured in two poster presentations at the 67<sup>th<\/sup> American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 \u2013 9, 2025, in Orlando, Florida.<\/p>\n<p>GB3226 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to simultaneously target ENL-YEATS, an epigenetic driver of leukemogenesis, and FLT3, a key oncogenic kinase mutated in approximately 30% of adult AML patients. The unique dual inhibition of these pathways may offer greater therapeutic benefit than FLT3 or menin inhibition alone. In preclinical studies, GB3226 demonstrated potent activity across AML patient-derived samples with diverse genotypes, and induced rapid tumor regression and significantly prolonged survival in xenograft models. GB3226 also exhibited favorable pharmacokinetics and tolerability in animal studies, and demonstrated additive or synergistic effects with current standard-of-care agents. These findings support further clinical development of GB3226 as a novel, differentiated therapeutic approach for patients with AML.<\/p>\n<p>\n        <strong>Poster Presentation Details<\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>A Phase 1 Study of GB3226, a Novel Dual Inhibitor of ENL-Yeats and FLT3, in Patients with Relapsed\/Refractory Acute Myeloid Leukemia<\/p>\n<p><strong>Presenting Author: <\/strong>Abhishek Maiti, MD Anderson Cancer Center, University of Texas, USA<\/p>\n<p>\n        <strong>Session Date and Presentation Time: <\/strong>December 6, 2025, 5:30 PM &#8211; 7:30 PM EST<\/p>\n<p><strong>Session Title: <\/strong>616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I<\/p>\n<p><strong>Location: <\/strong>Orange County Convention Center (OCCC) &#8211; West Halls B3-B4<\/p>\n<p>\n        <strong>Publication Number: <\/strong>1652<\/p>\n<p>\n        <strong>Title: <\/strong>GB3226, A Novel, Orally Active, First-in-Class Small Molecule Inhibitor of ENL-Yeats and FLT3 Kinase for the Treatment of Relapsed\/Refractory Acute Myeloid Leukemia<\/p>\n<p><strong>Presenting Author: <\/strong>Louis Renzetti, Galecto Inc., Copenhagen, Denmark<\/p>\n<p>\n        <strong>Session Date and Presentation Time: <\/strong>December 8, 2025, 6:00 PM &#8211; 8:00 PM EST<\/p>\n<p><strong>Session Title: <\/strong>802. Chemical Biology and Experimental Therapeutics: Poster III<\/p>\n<p><strong>Location: <\/strong>Orange County Convention Center (OCCC) &#8211; West Halls B3-B4<\/p>\n<p>\n        <strong>Publication Number: <\/strong>6106<\/p>\n<p>\n        <strong>About GB3226<\/strong><br \/>\n        <br \/>GB3226, an investigational candidate, is a potent and selective, orally administered, ENL-YEATS and FLT3 inhibitor of multiple genetic subsets of AML. It disrupts key oncogenic pathways by inhibiting these domains, showing potent activity in MLLr and NPM1c cell lines. Promising preclinical and\u00a0<em>in vivo<\/em> results highlight its efficacy in inhibiting leukemia cell growth and extending survival in AML models. In animal models, GB3226 exhibited superior efficacy to both FLT3 and menin inhibitors and was shown to inhibit cell proliferation in primary AML patient samples across multiple genotypes, including MLL-r, NPM1m, cKIT+, FLT3+, and TET2+. These mutations are often seen in AML and, in total, could account for greater than 30% of the AML patient population. Many of these mutations have proven difficult to treat with currently available regimens and therefore represent a significant unmet medical need. Based on preclinical data, the Company believes GB3226 has the potential to be additive or synergistic when used in combination with the current standard of care (azacitidine, venetoclax, cytarabine, gilteritinib, and revumenib).<\/p>\n<p>\n        <strong>About Galecto<\/strong><br \/>\n        <br \/>Galecto\u00a0is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company\u2019s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for the treatment of multiple genetic subsets of AML.\u00a0Galecto\u00a0intends to use its website as a means of disclosing material non-public information. For regular updates about\u00a0Galecto, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2EvE73wACBtFU1kE9k5yujcloHF9BmHT2KEJT8g-WGnhOqOL6hR7zXXEzAzaWFhB9EFFj2vLpX8lHyDZIHimKttejSUfCfByHJCEBV_cH9bsHA6caX8Gb8OtjGsJfCntCxSNQ7VokEUghdFKlnz24yGmiJrY6x1vKv0lChR1oU-YZ6rPJCgQGyyVIhjYnKIazs1YYSKvpaSDTn2PqTXxi-6lSX7_aQ04C9FQL-15w3ozWcmlNTbHMGP3ChFIFdZ79qChm9uGza7w5KQIEL0WdIsH575FvqyIF04BKRdBDx3wGKfqXwuT8OmLmnflHzjXW0GOxByo0bO-zqbT9FfClJDcqHUB7kh7RJb6NfiabWMg9Dcnk2cqguBcTF8nYdflQFzCuPNedQPJtACihQ3xCd8av43qDqcclbPKvNUgK8-riXWQBOOkG8_bYEurLsvZ5eF92EyCEgDM7_pvwhYtJphJI8wRBqtmoU3xagNpA9JjU-Wq_RHrnwxUIeVWIYAG9UqsHrM4AItzwEagEudvNB7dDoFUk5b5JiL_4Be18-pxaipWQmG2hKhYEuLlEsnZVaqIrPTizgqO3rwGsPP331VZET-aGYfguPpgK-vnH5DGUAXEdaZqxDcWmAM1_dcB9uMgOB_VhEyzU5TlUWHUQl4vEhP_ZFsWg9rQy7iet0Mku8tOAuermlw09JoTvMD3DAgc1BmuJvF1kpnfnxz63A==\" rel=\"nofollow\" target=\"_blank\">www.galecto.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto\u2019s preclinical and clinical development plans for GB3226 and its potential to address challenging genetic subsets of AML. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto&#8217;s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto\u2019s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto\u2019s filings with the Securities and Exchange Commission (SEC), including, but not limited to, Galecto\u2019s Annual Report on Form 10-K, as filed with the SEC on March 19, 2025, and Galecto\u2019s Quarterly Report on Form 10-Q, as filed with the SEC on May 8, 2025. These forward-looking statements represent Galecto&#8217;s judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.<\/p>\n<p>\n        <strong>For more information, contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Investors\/US<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Sandya von der Weid<br \/>svonderweid@lifesciadvisors.com<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">+41 78 680 0538<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjY4NDU3MTAtOWVhNS00OTlmLTg4NmUtM2QyMjEyODI0YTNlLTUwMDA2OTk5Ny0yMDI1LTExLTAzLWVu\/tiny\/Galecto-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured in two poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 \u2013 9, 2025, in Orlando, Florida. GB3226 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to simultaneously target ENL-YEATS, an epigenetic driver of leukemogenesis, and FLT3, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Galecto to Highlight GB3226 Program at ASH 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904341","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured in two poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 \u2013 9, 2025, in Orlando, Florida. GB3226 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to simultaneously target ENL-YEATS, an epigenetic driver of leukemogenesis, and FLT3, &hellip; Continue reading &quot;Galecto to Highlight GB3226 Program at ASH 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T16:32:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Galecto to Highlight GB3226 Program at ASH 2025\",\"datePublished\":\"2025-11-03T16:32:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/\"},\"wordCount\":867,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/\",\"name\":\"Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\",\"datePublished\":\"2025-11-03T16:32:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/galecto-to-highlight-gb3226-program-at-ash-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galecto to Highlight GB3226 Program at ASH 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/","og_locale":"en_US","og_type":"article","og_title":"Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk","og_description":"Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured in two poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 \u2013 9, 2025, in Orlando, Florida. GB3226 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to simultaneously target ENL-YEATS, an epigenetic driver of leukemogenesis, and FLT3, &hellip; Continue reading \"Galecto to Highlight GB3226 Program at ASH 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T16:32:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Galecto to Highlight GB3226 Program at ASH 2025","datePublished":"2025-11-03T16:32:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/"},"wordCount":867,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/","name":"Galecto to Highlight GB3226 Program at ASH 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==","datePublished":"2025-11-03T16:32:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjYxMiM3MjM3ODc4IzUwMDA2OTk5Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/galecto-to-highlight-gb3226-program-at-ash-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Galecto to Highlight GB3226 Program at ASH 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904341"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904341\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}